Gilead expects 6% growth in HIV drug sales in 2026, with sales targets of $800 million for Yeztugo.[1] Yeztugo (lenacapavir) is an injectable HIV pre-exposure prophylaxis (PrEP) drug given twice a year.[1][3] It was approved in the US in June 2025, in Europe as Yeytuo in August 2025, and in the UK recently.[1][2] In the Phase III PURPOSE 1 and PURPOSE 2 clinical trials, Yeztugo showed 100% and 99% protection against HIV, with zero infections in 2134 participants in one arm versus daily Truvada.[1][3] It has reached $150 million in preliminary sales by 2025 and has 85% US insurance coverage with zero premium on some policies.[1] Analysts confirm that the $800 million forecast for Yeztugo in 2026 represents an achievable 433% year-on-year growth.[1] Gilead has seven HIV drugs in the pipeline and supplies lenacapavir to sub-Saharan Africa.[1]